Nautilus Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Nautilus Biotechnology, Inc. on June 20, 2025. The Company is an emerging growth company incorporated in Delaware, with common stock (NAUT) trading on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Of the 126,148,469 shares outstanding as of the April 22, 2025 record date, 99,716,163 shares were represented at the meeting. Key outcomes include:
- Election of Class I Directors: Sujal Patel and Matthew McIlwain were elected to serve until the 2028 annual meeting.
- Accounting Firm Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Board Composition Changes: Former directors Vijay Pande and Michael Altman resigned effective the Annual Meeting. Matthew McIlwain resigned as a Class II director to be elected as a Class I director. The authorized number of directors was decreased to seven (7).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the new Board composition and the reduction of authorized directorships to seven.
- Confirm the tenure of newly elected Class I directors (Sujal Patel and Matthew McIlwain) through 2028.
- Review the voting statistics for the ratification of PricewaterhouseCoopers LLP, noting 137,708 votes against.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.